Changes in pneumococcal vaccine coverage in the Canadian Longitudinal Study on Aging (CLSA): An analysis based on the 2018–2021 follow-up 2 survey
PLOS One · 2026
DOI: 10.1371/journal.pone.0338213 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Giorgia Sulis und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: Pneumococcal Vaccines, Pneumococcal Infections, Vaccination Coverage. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canada Research Chairs.
Abstract (Originalsprache)
Introduction
Pneumococcal vaccination is recommended for older adults and individuals with chronic medical conditions (CMC) due to the high risk of invasive pneumococcal disease in these groups. Despite this, vaccination coverage in Canada remains below the national target of 80%, to be achieved by 2025. We conducted a new analysis of recently released data from the Canadian Longitudinal Study on Aging (CLSA), aimed at providing estimates of pneumococcal vaccine coverage from 2018–2021 among eligible adults, identifying sociodemographic disparities, and exploring changes over time since 2015.
Methods
The CLSA, a nationally representative cohort launched in 2011, recently released data collected during the second follow-up visit (FUP2; 2018–2021). We conducted a cross-sectional analysis of participant self-reported pneumococcal vaccination status, stratified by sociodemographic characteristics, receipt of influenza vaccine in the previous 12 months, and contact with family doctor in the previous 12 months. Logistic regression was used to identify factors associated with being newly vaccinated for pneumococcal disease as reported during FUP2 compared with three years earlier during follow-up 1 (FUP1; 2015–2018). We previously reported pneumococcal vaccination estimates for 2015–2018.
Results
Only 56.8% (95% CI: 55.8–57.7%; n = 10,530) of eligible study participants aged 65 years and older and 19.3% (95% CI: 18.1–20.5%; n = 4,055) of those aged
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.
- Methodological and Implementation Research Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
- Department of Epidemiology, Biostatistics and Occupational Health, School of Population and Global Health, Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada.
- Neuroepidemiology Research Unit, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
ORCID-Profile: Giorgia Sulis
Förderung
- Canada Research Chairs
Zitieren
APA
Sulis, G., Maredia, N., Wolfson, C., & Basta, N. E. (2026). Changes in pneumococcal vaccine coverage in the Canadian Longitudinal Study on Aging (CLSA): An analysis based on the 2018–2021 follow-up 2 survey. PLOS One. https://doi.org/10.1371/journal.pone.0338213
Vancouver
Sulis G, Maredia N, Wolfson C, Basta NE. Changes in pneumococcal vaccine coverage in the Canadian Longitudinal Study on Aging (CLSA): An analysis based on the 2018–2021 follow-up 2 survey. PLOS One. 2026. doi:10.1371/journal.pone.0338213
BibTeX
@article{Sulis2026,
author = {Sulis, Giorgia and Maredia, Nawal and Wolfson, Christina and Basta, Nicole E},
title = {Changes in pneumococcal vaccine coverage in the Canadian Longitudinal Study on Aging (CLSA): An analysis based on the 2018–2021 follow-up 2 survey},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0338213}
}
EUVIMED